Imugene names new advisory board members
This article was originally published in Scrip
Executive Summary
Australian biopharmaceutical company Imugene, which develops oncology drugs, has appointed Professor Dr Christoph Zielinski and Professor Dr Ursula Wiedermann to its scientific advisory board. Professor Zielinski is the director of the clinical division of oncology and chair of the department of medicine at the Medical University of Vienna, Austria. He is also coordinator of the comprehensive cancer centre at the university and the General Hospital in Vienna and is president of the Central European Cooperative Oncology Group (CECOG). Meanwhile, Professor Wiedermann is professor of vaccinology and head of the institute of specific prophylaxis and tropical medicine of the Medical University Vienna.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.